TABLE 5.
Drug susceptibility test results of phase III based on the established breakpoints
| Drug (concn [μg/ml])a | Site | No. of strains with:
|
Total no. of strains | |||
|---|---|---|---|---|---|---|
| S/Sa | R/Ra | R/Sa | S/Ra | |||
| Amikacin (1.0/1.0) | Site 1 | 14 | 26 | 0 | 1 | 41 |
| Site 2 | 32 | 0 | 0 | 0 | 32 | |
| Site 3 | 18 | 1 | 0 | 0 | 19 | |
| All sites | 64 | 27 | 0 | 1 | 92 | |
| Capreomycin (1.25/2.5) | Site 1 | 15 | 25 | 0 | 1 | 41 |
| Site 2 | 31 | 0 | 1 | 0 | 32 | |
| Site 3 | 17 | 2 | 0 | 0 | 19 | |
| All sites | 63 | 27 | 1 | 1 | 92 | |
| Ethionamide (2.5/5.0) | Site 1 | 14 | 26 | 0 | 1 | 41 |
| Site 2 | 30 | 2 | 0 | 0 | 32 | |
| Site 3 | 11 | 8 | 0 | 0 | 19 | |
| All sites | 55 | 36 | 0 | 1 | 92 | |
| Protionamide (1.25/2.5) | Site 1 | 20 | 17 | 2 | 2 | 41 |
| Site 2 | 30 | 2 | 0 | 0 | 32 | |
| Site 3 | 12 | 7 | 0 | 0 | 19 | |
| All sites | 62 | 26 | 2 | 2 | 92 | |
| Ofloxacin (2.0/2.0) | Site 1 | 33 | 8 | 0 | 0 | 41 |
| Site 2 | 32 | 0 | 0 | 0 | 32 | |
| Site 3 | 18 | 1 | 0 | 0 | 19 | |
| All sites | 83 | 9 | 0 | 0 | 92 | |
| Rifabutin (0.5/0.5) | Site 1 | 4 | 37 | 0 | 0 | 41 |
| Site 2 | 16 | 15 | 1 | 0 | 32 | |
| Site 3 | 9 | 10 | 0 | 0 | 19 | |
| All sites | 29 | 62 | 1 | 0 | 92 | |
| Linezolid (1.0/1.0) | Site 1 | 38 | 3 | 0 | 0 | 41 |
| Site 2 | 32 | 0 | 0 | 0 | 32 | |
| Site 3 | 21 | 0 | 0 | 0 | 19 | |
| All sites | 89 | 3 | 0 | 0 | 92 | |
a
BACTEC 460/BACTEC MGIT 960. S, susceptible; R, resistant.